CDC/Phil_ImagesLondon-based Vicebio Ltd has announced a US$100m Series B financing that will support Phase I testing of its bivalent RSV vaccine candidate VXB-241 and pushing development of another pipeline programme.
Brenus Pharma SAFrench Brenus Pharma SA has raised €22.2m (US$25m) to accelerate clinical trials of two precision cancer vaccines derived from tumour cell banks representing more than 200 tumour antigens.
UE 2024 - PEEuropean Commission President Ursula von der Leyen has revealed her nominees for new commissioners to lead the bloc for the next term from 2024 to 2029.
ImmunOs Therapeutics AG Swiss cancer and auto-immunity specialist ImmunOs Therapeutics AG has closed a Series C financing round of US$11m led by existing investors Gimv, Pfizer Ventures, Mission BioCapital, BioMed Partners and supported by new investor Double Point Ventures.
BIOCOM Interrelations GmbHAfter three and a half years of construction, the CDMO Richter Biologics has inaugurated its new multipurpose production facility that triples the CDMO’s capacity for the bacterial production of pDNA, vaccines, nanobodies and recombinant proteins.
Phoremost LtdBritish protein degrader specialist PhoreMost Ltd has extended its €33m Series B financing to $50M and plans to advance its oncology and inflammation degrader programmes.
Agri-biotech SOLASTA Bio Ltd. has raised US$14m in a Series A funding round led by Forbion. With the money, the UK company will advance its first-of-a kind peptide-based bioinsecticide.
AstraZenecaA Phase III trial evaluating AstraZeneca and Daiichi Sankyo’s potential “blockbuster” lung cancer drug Dato-DXd showed no significant improvement over standard chemotherapy. Investors reacted quickly: AstraZeneca’s share price dropped 5% following the announcement.
King's CollegeA new £12.5m Series B expansion brings Elipsogen Ltd’s total Series B funds raised to £43.25 million. The IgE antibody specialist will use the roceeds to support the delivery of clinical Proof of Concept for MOv18 IgE.
Hayo Therapeutics SASwiss HAYA Therapeutics SA has inked a US$1bn biobuck deal with pharma giant Eli Lilly to discover new lncRNA targets in obesity and related metabolic conditions.